These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 34093441)
41. Metabolic Bone Disease in the Context of Metastatic Neuroendocrine Tumor: Differentiation from Skeletal Metastasis, the Molecular PET-CT Imaging Features, and Exploring the Possible Etiopathologies Including Parathyroid Adenoma (MEN1) and Paraneoplastic Humoral Hypercalcemia of Malignancy Due to PTHrP Hypersecretion. Ranade R; Basu S World J Nucl Med; 2017; 16(1):62-67. PubMed ID: 28217023 [TBL] [Abstract][Full Text] [Related]
42. Hypercalcemia and Renal Mass: A Diagnostically Challenging Case. Karki S; Galiveeti S; Leung V Cureus; 2021 Jul; 13(7):e16718. PubMed ID: 34513354 [TBL] [Abstract][Full Text] [Related]
43. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma. Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108 [TBL] [Abstract][Full Text] [Related]
44. Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. Daskalakis K; Chatzelis E; Tsoli M; Papadopoulou-Marketou N; Dimitriadis GK; Tsolakis AV; Kaltsas G Endocrine; 2019 May; 64(2):384-392. PubMed ID: 30280284 [TBL] [Abstract][Full Text] [Related]
46. Pancreatic neuroendocrine tumor with extensive vascularisation and parathyroid hormone-related protein (PTHrP)--associated hypercalcemia of malignancy. Clemens P; Gregor M; Lamberts R Exp Clin Endocrinol Diabetes; 2001; 109(7):378-85. PubMed ID: 11573150 [TBL] [Abstract][Full Text] [Related]
47. Parathyroid hormone-related protein and hypercalcemia in pancreatic neuro-endocrine tumors. Rizzoli R; Sappino AP; Bonjour JP Int J Cancer; 1990 Sep; 46(3):394-8. PubMed ID: 2394507 [TBL] [Abstract][Full Text] [Related]
48. Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1. Milanesi A; Yu R; Geller SA; Burton D; Deftos LJ; Wolin EM Pancreas; 2011 May; 40(4):634-7. PubMed ID: 21483254 [TBL] [Abstract][Full Text] [Related]
49. Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma. Shivnani SB; Shelton JM; Richardson JA; Maalouf NM Endocr Pract; 2009 Apr; 15(3):234-9. PubMed ID: 19364692 [TBL] [Abstract][Full Text] [Related]
50. Malignant Hypercalcemia Due to the Ectopic Production of Calcitriol by an Abdominal Liposarcoma. Figueiredo A; Pereira T; Cabrera R; Simões-Pereira J; Leite V Cureus; 2023 Jan; 15(1):e33446. PubMed ID: 36751194 [TBL] [Abstract][Full Text] [Related]
51. Paraneoplastic hypercalcemia in a patient with adenosquamous cancer of the colon. Thompson JT; Paschold EH; Levine EA Am Surg; 2001 Jun; 67(6):585-8. PubMed ID: 11409809 [TBL] [Abstract][Full Text] [Related]
52. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Sato K; Onuma E; Yocum RC; Ogata E Semin Oncol; 2003 Oct; 30(5 Suppl 16):167-73. PubMed ID: 14613038 [TBL] [Abstract][Full Text] [Related]
53. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955. Blind E; Raue F; Meinel T; Wüster C; Ziegler R Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711 [TBL] [Abstract][Full Text] [Related]
54. Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study. Zacho MD; Iversen P; Villadsen GE; Baunwall SMD; Arveschoug AK; Grønbaek H; Dam G Scand J Gastroenterol; 2021 Mar; 56(3):289-297. PubMed ID: 33470864 [TBL] [Abstract][Full Text] [Related]
55. Hypercalcemia as the first finding of late recurrence of a PTHrP neuroendocrine tumor of the pancreas. Febrero B; Gómez B; Ruiz-Manzanera JJ; Ros-Madrid I; Rodríguez JM Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):31-32. PubMed ID: 38350837 [No Abstract] [Full Text] [Related]
56. Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy. Michigami T; Yamato H; Suzuki H; Nagai-Itagaki Y; Sato K; Ozono K J Endocrinol; 2001 Nov; 171(2):249-57. PubMed ID: 11691644 [TBL] [Abstract][Full Text] [Related]
57. Humoral Hypercalcemia in Uterine Cancers: A Case Report and Literature Review. Motilal Nehru V; Garcia G; Ding J; Kong F; Dai Q Am J Case Rep; 2017 Jan; 18():22-25. PubMed ID: 28057913 [TBL] [Abstract][Full Text] [Related]
58. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432 [TBL] [Abstract][Full Text] [Related]
59. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population. Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539 [TBL] [Abstract][Full Text] [Related]
60. Pancreatic metastases in patients with neuroendocrine neoplasms: A multi-centre cohort study. Tsoli M; Daskalakis K; Wedin M; Angelousi A; Povlsen S; Srirajaskanthan R; Giovos G; Weickert MO; Kogut A; Kos-Kudla B; Oleinikov K; Grozinsky-Glasberg S; Kaltsas G J Neuroendocrinol; 2023 Apr; 35(4):e13269. PubMed ID: 37102337 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]